The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Renal impairment after chemotherapy in lung (LC), colorectal (CRC), and breast cancer (BC) patients (pts) from the Henry Ford Health System (HFHS) tumor registry.
Laura Chu
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Marianne Ulcickas Yood
Research Funding - Genentech
Mahmoud Loghman-Adham
Stock Ownership - Roche
Karen Wells
No relevant relationships to disclose
Deborah Casso
Research Funding - Genentech
Susan A. Oliveria
Research Funding - Genentech
Wei Dong
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche